Division of Endocrinology, Children's National Hospital, Washington, District of Columbia, USA.
The George Washington University School of Medicine, Washington, District of Columbia, USA.
Horm Res Paediatr. 2022;95(4):397-401. doi: 10.1159/000525227. Epub 2022 May 24.
There is emerging speculation that the inflammatory state associated with SARS-CoV-2 infection may trigger autoimmune conditions, but no causal link is established. There are reports of autoimmune thyroiditis and adrenal insufficiency in adults post-COVID-19. We describe the first pediatric report of adrenal insufficiency and autoimmune hypothyroidism after COVID-19.
A 14-year-old previously healthy girl, with vitiligo, presented in shock following 1 week of fever, lethargy, diarrhea, and vomiting. Three weeks prior, she had congestion and fatigue and known familial exposure for COVID-19. Labs were remarkable for sodium 129 mmol/L, K 4.3 mmol/L, creatinine 2.9 mg/dL, hemoglobin 8.3 g/dL, and positive COVID-19 PCR and SARS-CoV-2 IgG. She was resuscitated with normal saline and required pressor support. EKG showed abnormal repolarization presumed secondary to myocarditis. She met the criteria for multisystem inflammatory syndrome in children (MIS-C), received intravenous immune globulin and IL-1R antagonist and was admitted for intensive care. Persistent hypotension despite improved inflammatory markers and undetectable cortisol led to initiation of hydrocortisone. She was then able to rapidly wean off pressors and hydrocortisone within 48 h. Thereafter, tests undertaken for persistent bradycardia confirmed autoimmune hypothyroidism with TSH 131 μU/mL, free T4 0.85 ng/dL, and positive thyroid autoantibodies. Basal and stimulated cortisol were <1 μg/dL on a standard 250 μg cosyntropin stimulation test, with baseline ACTH >1,250 pg/mL confirming primary adrenal insufficiency. Treatment was initiated with hydrocortisone, levothyroxine, and fludrocortisone. Adrenal sonogram did not reveal any hemorrhage and anti-adrenal antibody titers were positive. The family retrospectively reported oligomenorrhea, increased salt craving in the months prior, and a family history of autoimmune thyroiditis. The cytokine panel was notably different from other cases of MIS-C.
This is the first pediatric report, to our knowledge, of primary adrenal insufficiency and hypothyroidism following COVID-19, leading to a unique presentation of autoimmune polyglandular syndrome type 2. The initial presentation was attributed to MIS-C, but the subsequent clinical course suggests the possibility of adrenal crisis. It remains unknown if COVID-19 had a causal relationship in triggering the autoimmune adrenal insufficiency and hypothyroidism.
目前有观点认为,与 SARS-CoV-2 感染相关的炎症状态可能引发自身免疫性疾病,但目前尚未建立因果关系。有报道称,COVID-19 后成年人会出现自身免疫性甲状腺炎和肾上腺功能不全。我们描述了首例 COVID-19 后儿童发生肾上腺功能不全和自身免疫性甲状腺功能减退症的病例。
一名 14 岁既往健康的女孩,患有白癜风,在 COVID-19 家族暴露后,出现发热、乏力、腹泻和呕吐 1 周后出现休克。3 周前,她出现鼻塞和乏力。实验室检查示血钠 129mmol/L、血钾 4.3mmol/L、肌酐 2.9mg/dL、血红蛋白 8.3g/dL,COVID-19 PCR 和 SARS-CoV-2 IgG 阳性。她接受生理盐水复苏治疗,并需要升压支持。心电图显示异常复极,推测继发于心肌炎。她符合儿童多系统炎症综合征(MIS-C)的标准,接受了静脉注射免疫球蛋白和 IL-1R 拮抗剂,并入住重症监护病房。尽管炎症标志物改善,但仍持续低血压,皮质醇水平无法检测,故开始使用氢化可的松。此后,持续心动过缓的检查结果证实为自身免疫性甲状腺功能减退症,促甲状腺激素(TSH)131μU/mL,游离甲状腺素(FT4)0.85ng/dL,甲状腺自身抗体阳性。标准 250μg 促皮质素兴奋试验基础和刺激皮质醇<1μg/dL,基础 ACTH>1250pg/mL,证实为原发性肾上腺功能不全。给予氢化可的松、左甲状腺素和氟氢可的松治疗。肾上腺超声未见出血,抗肾上腺抗体滴度阳性。该家族回顾性报告,患儿在发病前几个月存在月经稀发、盐摄入增加,以及自身免疫性甲状腺炎家族史。细胞因子谱与其他 MIS-C 病例明显不同。
据我们所知,这是首例 COVID-19 后发生原发性肾上腺功能不全和甲状腺功能减退症,导致 2 型自身免疫性多腺体综合征的独特表现。最初表现归因于 MIS-C,但随后的临床病程提示可能发生肾上腺危象。目前尚不清楚 COVID-19 是否与自身免疫性肾上腺功能不全和甲状腺功能减退症的发生存在因果关系。